Get the Stockscreener App
3.32
1.84%
0.06
OncoCyte Corporation stock is traded at $3.32, with a volume of 14,324.
It is up +1.84% in the last 24 hours and up +6.41% over the past month.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
See More
Previous Close:
$3.26
Open:
$3.22
24h Volume:
14,324
Relative Volume:
0.22
Market Cap:
$94.95M
Revenue:
$709.00K
Net Income/Loss:
$-43.14M
P/E Ratio:
-0.7313
EPS:
-4.54
Net Cash Flow:
$-20.35M
1W Performance:
-1.48%
1M Performance:
+6.41%
6M Performance:
+36.07%
1Y Performance:
+25.28%
1-Day Range:
$3.185
$3.32
1-Week Range:
$3.185
$3.40
52-Week Range:
$1.922
$4.75
OncoCyte Corporation Stock (OCX) Company Profile
Name
OncoCyte Corporation
Sector
Industry
Phone
510-775-0515
Address
1010 Atlantic Avenue, Suite 102, Alameda, CA
Compare OCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
3.32 | 96.38M | 709.00K | -43.14M | -20.35M | -4.54 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
OncoCyte Corporation Stock (OCX) Latest News
Midday Stock Roundup: GEN Restaurants Down. BJ’s Restaurants Up - Orange County Business Journal
Lake Street Capital Forecasts Strong Price Appreciation for OncoCyte (NASDAQ:OCX) Stock - Defense World
Lake Street Raises Price Target for OncoCyte (OCX) to $8.00 | OC - GuruFocus
Lake Street Raises Price Target for OncoCyte (OCX) to $8.00 | OCX Stock News - GuruFocus
Oncocyte (OCX) Gains Favorable Reimbursement for GraftAssureCore Test | OCX Stock News - GuruFocus
OncoCyte (OCX) Price Target Raised Amid Reimbursement Boost | OC - GuruFocus
OncoCyte reports Medicare boosts reimbursement for GraftAssureCore - TipRanks
OncoCyte (OCX) Price Target Raised Amid Reimbursement Boost | OCX Stock News - GuruFocus
OncoCyte price target raised to $8 from $5 at Lake Street - TipRanks
Oncocyte Corp Says New CMS Reimbursement Price Rate Of $2,753 Per Result For Graftassurecore Assay - marketscreener.com
Medicare Approves 24% Higher Payment for Oncocyte's Transplant Test: $1B Market Opportunity Expands - Stock Titan
Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology - TradingView
OncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiative - MSN
OncoCyte Corp’s Earnings Call: Optimism Amid Challenges - TipRanks
OncoCyte (NASDAQ:OCX) Earns “Buy” Rating from Needham & Company LLC - Defense World
OncoCyte (OCX) Seeks FDA Approval by 2026 - GuruFocus
OncoCyte Corporation (NASDAQ:OCX) Q1 2025 Earnings Call Transcript - Insider Monkey
Needham maintains Buy on OncoCyte, price target at $4.25 - Investing.com Australia
Needham maintains Buy on OncoCyte, price target at $4.25 By Investing.com - Investing.com Nigeria
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic Advances in Transplant Testing ... - Yahoo Finance
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic - GuruFocus
OncoCyte (OCX) Maintains 'Buy' Rating and Price Target by Needha - GuruFocus
Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations By Investing.com - Investing.com Nigeria
OncoCyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations - Investing.com
OncoCyte: Q1 Earnings Snapshot - San Antonio Express-News
OncoCyte Corp (OCX) Q1 2025 Earnings: Revenue Soars to $2.1 Mill - GuruFocus
Oncocyte Reports Q1 2025 Results and Business Progress - The Manila Times
Oncocyte Corp. Reports Q1 2025 Revenue of $2.1 Million and Plans Company Renaming - Nasdaq
Oncocyte Corp SEC 10-Q Report - TradingView
Oncocyte to Release First Quarter 2025 Results on May 12, 2025 - The Manila Times
Oncocyte To Release First Quarter 2025 Results On May 12, 2025 - Barchart.com
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
Geode Capital Management LLC Has $326,000 Stock Position in OncoCyte Co. (NASDAQ:OCX) - Defense World
Oncocyte Provides Positive Update on Clinical Trial Progress | O - GuruFocus
Why Tesla Stock Hit the Brakes Today - The Globe and Mail
AP PHOTOS: US stocks sink after a weak report on the economy - The Globe and Mail
Oncocyte (OCX) Advances Towards Crucial Clinical Trial for Trans - GuruFocus
Oncocyte advances toward clinical trial for transplant test By Investing.com - Investing.com India
Oncocyte advances toward clinical trial for transplant test - Investing.com Australia
Oncocyte Provides Positive Update on Clinical Trial Progress - The Manila Times
Oncocyte Provides Positive Update on Clinical Trial Progress | OCX Stock News - GuruFocus
Oncocyte Provides Positive Update On Clinical Trial ProgresS - marketscreener.com
Leading US Transplant Centers Back Oncocyte's Revolutionary Rejection Test Clinical Trial - Stock Titan
OncoCyte (NASDAQ:OCX) Trading Down 3.1% – Here’s What Happened - Defense World
Oncocyte study links blood test to kidney rejection markers - Investing.com
Economic Uncertainty Weighs on PayPal - The Globe and Mail
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Val - GuruFocus
Oncocyte (OCX) Unveils Promising Data on Transplant Rejection Te - GuruFocus
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity | OCX Stock News - GuruFocus
OncoCyte Corporation Stock (OCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):